The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention.
The Bolger conference on PDE-5 inhibition and HIV risk: implications for health policy and prevention.
复制标题
Bolger 会议关于 PDE-5 抑制和 HIV 风险：对卫生政策和预防的影响。
DOI：
10.1111/j.1743-6109.2006.00323.x
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Latini,David
中科院分区：
文献类型：
--
作者：
Rosen,RaymondC;Catania,JosephA;Ehrhardt,AnkeA;Burnett,ArthurL;Lue,TomF;McKenna,Kevin;Heiman,JuliaR;Schwarcz,Sandy;Ostrow,DavidG;Hirshfield,Sabina;Purcell,DavidW;Fisher,WilliamA;Stall,Ron;Halkitis,PerryN;Latini,David
简介最近的报告表明，使用 5 型磷酸二酯酶 (PDE-5) 抑制剂与某些个体的高风险性行为和 HIV 传播率增加有关。AimA 由国家心理健康研究所 (NIMH) 资助，召开了多学科会议，以评估该主题的科学研究、临床和伦理考虑以及公共政策影响。主要结果指标关于 PDE-5 抑制剂对性行为影响的已发表和未发表的研究结果；方法相关学科（例如公共卫生、流行病学、医学伦理学、泌尿学、心理学）的主要研究人员参加了为期两天的会议，其中包括政府、科学和监管机构（疾病控制中心、食品和药物管理局、NIMH 和国家药物滥用研究所）的代表。小组成员对实质性研究领域进行了批判性评论，随后就每个主题进行了问答。第二天，召开了工作组会议，以确定三个主要领域的关键差距和优先事项：(i) 研究和评估需求； (ii) 预防策略和临床管理问题；结果研究需求和优先事项分为四个具体领域：(i) 基础和临床/实验室研究； (ii) 流行病学和危险因素； (iii) 社会行为过程和干预措施； (iv) 预防/政策和教育需求。现有数据中已确定的差距包括高危人群（例如异性恋者的风险、男男性行为人群的风险概况）以及 PDE-5 抑制剂在 HIV 血清转化中的具体作用。具体重点领域是需要安全性行为咨询、全面的性传播感染 (STI) 筛查和有指征时的随访、避免潜在危险的药物相互作用，以及睾酮替代疗法对雄激素减少和其他性腺功能减退症状的 HIV 阳性男性的潜在益处。结论 召开了一次关于 PDE-5 抑制和 HIV 风险主题的会议。这份“白皮书”总结了会议的调查结果以及对未来研究的建议。
IntroductionRecent reports have linked the use of phosphodiesterase type 5 (PDE‐5) inhibitors with increased rates of high‐risk sexual behavior and HIV transmission in some individuals.AimA National Institute of Mental Health (NIMH)‐funded, multidisciplinary conference was convened to evaluate scientific research, clinical and ethical considerations, and public policy implications of this topic.Main Outcome MeasuresPublished and unpublished findings on effects of PDE‐5 inhibitors on sexual behavior; published guidelines and management recommendations.MethodsLeading investigators in relevant disciplines (e.g., public health, epidemiology, medical ethics, urology, psychology) participated in a 2‐day meeting, including representatives of government, scientific, and regulatory agencies (the Centers for Disease Control, Food and Drug Administration, NIMH, and the National Institute on Drug Abuse). Panelists provided critical reviews of substantive areas of research, followed by question and answer sessions on each topic. On the second day, working groups were convened to identify critical gaps and priorities in three major areas: (i) research and evaluation needs; (ii) prevention strategies and clinical management issues; and (iii) policy and prevention implications.ResultsResearch needs and priorities were categorized into four specific areas: (i) basic and clinical/laboratory research; (ii) epidemiology and risk factors; (iii) social‐behavioral processes and interventions; and (iv) prevention/policy and educational needs. Identified gaps in the available data include populations at risk (e.g., risk among heterosexuals, risk profiles among subpopulations of men who have sex with men) and the specific role of PDE‐5 inhibitors in HIV seroconversion. Specific areas of emphasis were the need for safer sex counseling, comprehensive sexually transmitted infection (STI) screening and follow‐up when indicated, avoidance of potentially dangerous drug interactions, and potential benefits of testosterone replacement for HIV‐positive men with decreased androgen and other symptoms of hypogonadism.ConclusionsA conference was convened on the topic of PDE‐5 inhibition and HIV risk. This “white paper” summarizes the findings of the conference and recommendations for future research.